Drug Profile
NB 1002
Alternative Names: GLP-2- XTEN™; NB1002Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Amunix
- Developer Naia Limited
- Class
- Mechanism of Action Glucagon-like peptide 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders; Short bowel syndrome
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA
- 08 Feb 2022 Amunix has been acquired by Sanofi
- 28 Nov 2021 No recent reports of development identified for preclinical development in Short-bowel-syndrome in USA